ABSTRACT
The2022Nobel Prize in Physiology or Medicine was awarded to Swedish biologist Svante Paabo forhis decisive contribution to paleoanthropogenomics and human origins.There are various theories about theorigin of human beings,and the current mainstream view is:out of the African doctrine.In other words,ancienthumans had about three times of migrations.The first time wasHomo erectus,the second was Neanderthals andDenisovans,and the third was the ancestors of modern humans.All migrated from Africa to Eurasia.Whilepioneering a new discipline,paleoanthropogenomics,Svante Paabo has been refining the"Out of Africa Theory".With the help of various biological techniques,he delved into the origin of human beings from the perspective ofgenomics and found that some genetic imprints from ancient humans were retained in our bodies.For example,the STAT2gene and TLR gene associated with immunity,the EPAS1gene that contributes to hypoxic respirationand the six genes of chromosome3are highly positively correlated with the incidence of COVID-19.Thisresearch means that we can go back to the root of certain diseases,rather than limiting our eyes to the genesthemselves,and exploring where a gene comes from will be a new way of studying diseases.We summarized hisinnovations in related biotechnology in the process of research,his exploration of ancient humans based onmitochondrial and nuclear genes and related results,and introduced some genes derived from ancient humans andtheir related information
ABSTRACT
COVID-19 paused people lives and recombine various industry operation system. The China's Belt and Road Initiative have been intensively studied for their role in healthcare industry, the nations among them came together to defeat COVID-19 by building new healthcare system for protect public health condition. Pandemic periods inspect the previous healthcare supply chain system inefficiency in the operation situation matches with the current social development. This article compares the traditional healthcare supply chain management and novel one developing with the medical pandemic. Simultaneously, the new supply chain process illustrates the new pattern healthcare supply chain under COVID-19 in China's Belt and Road Initiative countries. Taken together, the results of this article, potentially representing a novel healthcare supply chain developing process during pandemic in China's Belt and Road Initiative. © The Authors, published by EDP Sciences, 2021.
ABSTRACT
BACKGROUND: Published reports on tocilizumab in COVID-19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues. METHODS: This open-label trial, structured according to Simon's optimal design, aims to identify factors predicting which patients could benefit from anti-IL6 strategies and to enhance the design of unequivocal and reliable future randomized trials. A total of 46 patients with COVID-19 pneumonia needing of oxygen therapy to maintain SO2 > 93% and with recent worsening of lung function received a single infusion of tocilizumab. Clinical and biological markers were measured to test their predictive values. Primary end point was early and sustained clinical response. RESULTS: Twenty-one patients fulfilled pre-defined response criteria. Lower levels of IL-6 at 24 h after tocilizumab infusion (P = 0.049) and higher baseline values of PaO2/FiO2 (P = 0.008) predicted a favourable response. CONCLUSIONS: Objective clinical response rate overcame the pre-defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.